


RSC Advances



This article can be cited before page numbers have been issued, to do this please use: D. Kleeblatt, M. Becker, M. Ploetz, M. Schönherr, A. Villinger, M. Hein, J. Eberle, M. Kunz, Q. Rahman and P. Langer, *RSC*



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Synthesis and Bioactivity of *N*-glycosylated 3-(2-Oxo-2- arylethylidene)-indolin-2-ones

Dennis Kleeblatt,^a Martin Becker,^a Michael Plötz,^b Madeleine Schönherr,^c Alexander Villinger,^a Martin Hein,^a Jürgen Eberle,^b Manfred Kunz,^c Qamar Rahman,^{a,d} Peter Langer*^{a,c}

^a Institut für Chemie, Universität Rostock, Albert-Einstein-Str. 3a, 18059 Rostock, Germany

^b Charité Centrum 12 für Innere Medizin und Dermatologie, Hauttumorzentrum, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany

^c Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinik Leipzig, Philipp-Rosenthal-Str. 23-25, 04103 Leipzig, Germany


^d Amity University, Lucknow Campus, Viraj Khand-5, Gomti Nagar, Lucknow – 226010, India

^e Leibniz-Institut für Katalyse e. V. an der Universität Rostock, Albert-Einstein-Str. 29a, 18059 Rostock, Germany

Fax: +49 (381)4986412, E-mail: peter.langer@uni-rostock.de

Abstract: *N*-Glycosyl-3-alkylideneoxindoles, *N*-glycosylated 3-(2-oxo-2-arylethylidene)indolin-2-ones, were prepared by reaction of isatin-*N*-glycosides with substituted acetophenones. The biological activities of these new compounds revealed significant antitumor activity in melanoma human cell lines. Inhibition of cell proliferation and loss of cell viability were strongly enhanced by the combination with the death ligand TRAIL (TNF-related apoptosis-inducing ligand). The antitumor effects were related to the inhibition of the survival pathway of c-Jun and JNK2 (Jun N-terminal kinase).

Keywords: isatines, indirubin analogues, carbohydrates, heterocycles



Graphical abstract

Introduction

The natural product indirubin (**1**) is an isomer of the blue dye indigo, which has, in contrast to indigo, a violet colour (Figure 1). During the isolation of indigo from natural sources, as well as during its industrial synthesis, indirubin is formed as a by-product and is responsible for the reddish shine. In addition, indirubin is the pharmacologically active substance of the traditional chinese medicinal recipe *Danggui Longhui Wan*, which has been used for the treatment of myelocytic leukemia.¹ The biological activity of indirubin has been related to the inhibition of cyclin dependent kinases (CDKs).² During the last years, inhibition of CDKs is becoming an attractive research field for combating cancer and other diseases, which are related to hyperproliferation.³ Indirubin and its substituted derivatives are not only potent inhibitors of cyclin-dependent kinases (CDKs)², but also of several other kinases, such as glycogen synthase kinase-3 (GSK-3).⁴ For example, 5-substituted indirubins displayed high inhibitory potency toward various CDKs and GSK-3 β .^{2,4} Also several *O*- and *N*-glycosylated indigoid dyes have been synthesized in recent years.⁵ Many of the compounds studied so far exhibit higher antiproliferative activity toward human cancer cells in vitro than their non-glycosylated analogues. Notably, both deprotected and protected *N*-glycosides may be of pharmacological relevance.⁶ For example, the biological activity of so called 'Natura', i. e. acetyl-protected β -D-xylopyranosyl-*N*-isoindigo, was reported to be higher than that of its deprotected analogue.^{6a}

In 2006, our group published the first synthesis of *N*-glycosylated indirubins.⁷ We also reported significant activities of several derivatives against various human cancer cell lines. Based on these results, other glycosylated and non-glycosylated derivatives and heteroanalogues of indirubin and isoindigo have been synthesized.⁸ Some of them, especially the thia-analogous indirubin-*N*-glycosides, have shown substantial activity against different human cancer cell lines.^{8c} In all these studies, we have found that the presence of a carbohydrate moiety located at the nitrogen atom of the heterocycle resulted in a significant increase of the anti-cancer activity.

In the course of our program related to the development of new, biologically active indirubin derivatives, we turned our attention to 3-alkylideneoxindoles, such as **2**, which can be

regarded as structurally simplified analogues of indirubin (Figure 1). We assumed that these structurally more flexible structures might better interact with the reactive center of an enzyme, which should lead to an enhanced biological activity. WOODARD *et al.* studied the activity of several *non-glycosylated* 3-alkylideneoxindoles as CDK inhibitors.^{9a} They reported a very high inhibition in case of derivative **3b** containing a halogen substituent. In contrast, only a weak inhibition was observed for unsubstituted derivative **3a** (Figure 2). BELENKAYA *et al.* reported anti-malaria activity of nitro substituted compound **3f**.^{9b}

Herein, we report what is, to the best of our knowledge, the first synthesis of *N*-glycosylated 3-alkylideneoxindoles and their antitumor activity in human melanoma cell lines. During the optimization of the biological activity, the most promising substitution patterns were selected based on known non-glycosylated derivatives.⁹




Figure 1. Indirubin (**1**) and 3-alkylideneoxindole **2**





Figure 2. Known biologically active non-glycosylated 3-alkylideneoxindoles


Results and Discussion

Isatin-*N*-glycoside **7a** was prepared, following our previously reported procedure,⁸ by reaction of L-rhamnose with aniline, acetylation and subsequent cyclization with oxalyl chloride (Scheme 1). Likewise, derivatives **7b**, **7c** and **7d** were prepared from D-mannose, D-glucose and D-galactose, respectively.^{6b,7b,10} The condensation of isatin-*N*-glycoside **7a** with acetophenone afforded *N*-glycosylated 3-alkylideneoxindole **9a** in up to 71% yield (Scheme 2). The reaction was optimized based on our previous experience with indirubin-*N*-glycosides and their heteroanalogous compounds,⁸ and based on known chemistry of non-glycosylated 3-alkylideneoxindoles.⁹ We tried several conditions for the condensation reaction and found that a two-step procedure worked best in our hands. The first step was the aldol reaction of the acetophenone with the carbonyl group (C-3) of the isatin-*N*-glycoside (Scheme 2). For this reaction step we used triethylamine as the base and ethanol as the solvent at a temperature of 20 °C. Only in case of parent acetophenone no additional solvent was used. In two cases we could isolate and characterize the aldol addition products, which were formed as diastereomeric mixtures, because of the new stereocenter at C-3. The ratio of the diastereomers was found to be about 2:1, but we did not investigate the configuration of the main/ minor isomer at C-3. In general, it was sufficient to isolate the crude products, by simple distillation of the solvent from the reaction mixture, to be used as the starting materials in the following step. The purified or the crude products were reacted with mesyl chloride, in the presence of triethylamine (and in some cases in the additional presence of DMAP), to give the desired dehydrated final products. After workup and purification, the products could be isolated in 71% yield.

The preparative scope was next studied (Table 1). The condensation of isatin-*N*-glycoside **7a-d** with various substituted acetophenones afforded *N*-glycosyl-3-alkylideneoxindoles **9a-m** in 45 - 78% yields (based on **7**).



Scheme 1. Synthesis of 1-(2,3,4-tri-*O*-acetyl-β-L-rhamnopyranosyl)isatin (**7a**). *Reagents and conditions:* (i) PhNH₂, EtOH (abs.), 20°C, 24 h; (ii) Ac₂O, pyridine, 0 °C, 12 h; (iii) oxalyl chloride (10 equiv.), AlCl₃ (1 equiv.), 55°C, 1.5 h, then chromatographic separation of the anomers.



















Scheme 2. Synthesis of **9a**. *Reagents and conditions:* (i) NEt_3 (1 eq.), EtOH 20 °C, 6-10 h. (ii) MsCl , NEt_3 , (DMAP), CH_2Cl_2 , 0-20 °C, 2 h, 20°C, 6-8 h.

For the overall reaction, using crude intermediates **8** for the final dehydration step, we observed a trend to higher yields for acetophenones containing electron-withdrawing substituents. The highest yields were observed for the nitro-substituted derivative, while the lowest yield was observed for the methoxy-substituted derivatives. This result is surprising, because of the lower nucleophilicity of the acceptor-substituted acetophenones.

Table 1. Synthesis and biological activity of acetyl protected *N*-glycosyl-3-(2-oxo-2-arylethylidene)indolin-2-ones **9a-m** (IC_{50} values for the tests of selected

compounds **9** in the melanoma cell line SK-Mel 147). The intermediately formed *N*-glycosylated 3-hydroxy-3-(2-oxo-2-arylethyl)indolin-2-ones **8** are also given (when isolated).

7	8 Yield	9 Yield	IC ₅₀ (μM) (mean +/- SD)
	 93%	 71% ^b	-
	 95%	 45% ^a (80% ^b)	4.4 +/- 0.5
		 78% ^a	4.3 +/- 0.7
		 49% ^a	2.8 +/- 0.6
		 65% ^a	4.2 +/- 0.4
		 70% ^a	6.0 +/- 0.6



^a Yields of isolated products **9** based on **7** using crude intermediate **8** for the dehydration step

^b Yields of isolated products **9** based on purified intermediate **8** used for the dehydration step

For the structure elucidation of compounds **9** two dimensional NMR experiments (^1H , ^1H -COSY, HSQC and ^1H , ^1H -NOESY) were carried out. In the ^1H , ^1H -NOESY spectra, the missing correlation between H-8 and H-4 (Figure 3) was a first, but unreliable indication of the *E*-configuration of the double bond between C-3 and C-8. Furthermore, the β -configuration of the carbohydrate substituents could be clearly shown by the correlation signals of H-1', H-3' and H-5' in the ^1H , ^1H -NOESY spectra (only β -configured starting isatin-*N*-glycosides were applied for the reactions). These correlations can appear in case of β -L-rhamno configured substituents, when they have a $^1\text{C}_4$ - (or similar) conformation, as well as in case of the other investigated carbohydrate substituents, when they have a $^4\text{C}_1$ -conformation. The above mentioned correlations were observed for all studied examples. Additionally, the structure of **9c** was independently confirmed by X-ray crystal structure analysis (Figure 4).¹¹ Here, the *E*-configuration of the double bond as well as the anomeric β -configuration and $^1\text{C}_4$ -conformation of the sugar moiety was clearly proven. Because of comparable NMR data of all the 3-(2-oxo-2-arylethylidene)indolin-2-ones, we assumed that all these compounds possess an *E*-configured double bond.




Figure 3. ^1H , ^1H -NOESY correlations for compound **9c**




Figure 4. X-ray structure image of compound **9c** (ORTEP plot with displacement ellipsoids at the 50 % probability level).

We also tried to remove the acetyl protecting groups from the carbohydrate substituents of compounds **9**. Therefore, typical methods under basic (e.g. 1% methanolic sodium methanolate)¹² as well as acidic conditions (hydrogen chloride in methanol) were applied. However, it was not possible to isolate the deprotected products from the reaction mixture. The result can be explained by a retro-aldol reaction as the formation of the corresponding acetophenone and of the isatin-*N*-glycoside was detected. However, as mentioned in the introduction, acetyl-protected glycosylated isindigo and indirubin derivatives proved, in some cases even more active than their deprotected analogues.^{6a} Therefore, we studied the pharmacological activity of our acetylated products and, in fact, interesting biological effects were observed which are outlined below.

In previous studies, we had investigated the biological activity of compound **9b** in melanoma cell lines SK-Mel-19, SK-Mel-29, SK-Mel-103 and SK-Mel-147 and observed only moderate direct activities in these cells.^{8c} In the present work, we studied the growth inhibitory activities (IC₅₀) of selected examples of various derivatives of derivatives **9** (Table 1). Here, we focussed on cell line SK-Mel-147 in order to put an emphasis on the differences between the individual substances. This cell line is characterized by a very high proliferative activity,

which may mirror the situation of highly aggressive metastatic cells in the human system. We selected the derivatives for biotests only those compounds which are stable in water for an extended period of time. Compounds which tend to be slightly unstable in aqueous solution were not tested in order to avoid misleading biological results. Those derivatives containing a β -L-rhamnosyl substituent revealed slightly higher activities than the mannosylated compounds. The highest activity was found for the chloro-substituted derivative **9d**. The higher growth inhibitory activity of derivative **9b** in our current experiments (IC₅₀ value: 4.4 +/- 0.5), as compared to our earlier results (IC₅₀ value: 27.2 +/- 1.3),^{8c} may be explained by i) culture conditions, ii) the different incubation times applied (48 h in current vs. 24 h in previous experiments) as well as by iii) two different assays, used (WST-1 in previous vs. XTT assay in current experiments). In addition, human benign dermal fibroblasts were used here as controls, and the IC₅₀ values of indirubin derivatives were significantly higher in fibroblasts than in melanoma cells (9b: 8.8 +/- 1.1 μ M; 9c: 32.9 +/- 0.9 μ M; 9d: 9.1 +/- 0.7 μ M; 9e: 9.5 +/- 0.3 μ M; 9f: 11 +/- 1.5 μ M; 9h: 19.3 +/- 0.9 μ M; 9i: 9.6 +/- 2.4 μ M; cf. Table 1).

Further biological effects of the *N*-glycosylated 3-(2-oxo-2-arylethylidene)indolin-2-one derivatives **9c**, **9d**, **9e**, **9f**, **9i**, **9j**, **9k** and **9m** were exemplary investigated in the frequently investigated human melanoma cell line A-375¹³, which is well characterized for apoptosis regulation. In particular, apoptosis regulation by the cytokine and death ligand TRAIL (TNF-related apoptosis-inducing ligand) is well described in this cell line.^{14,15} Cell viability was monitored by calcein staining and flow cytometry. The applied concentrations of 10 μ M of the indirubin derivatives resulted in a significant reduction of cell viability after 24 h (20% - 30%; Figure 5a). We had previously reported that indirubin derivatives, as also their heteroanalogous compounds, can strongly enhance apoptosis induced by death ligand TRAIL.^{8,14} Thus, combinations with TRAIL were also tested for the new series of *N*-glycosylated 3-(2-oxo-2-arylethylidene)indolin-2-ones. Whereas TRAIL (20 ng/ml) alone showed only moderate effects on A-375 cell viability (20% reduction), the combinations dramatically reduced the numbers of viable cells (50% - 90% reduction; Figure 5a).

Decreased cell viability also exerted a strong impact on cell proliferation, monitored in A-375 cells here by WST-1 assay. Thus, inhibition of cell proliferation upon combination treatment with TRAIL ranged between 70% and 90% (Figure 5b). Direct cytotoxicity on the other hand remained unaffected at this time, as determined by LDH release in cell culture supernatants (data not shown). Cell proliferation was also determined in real time. In fact, A-375 cells were still proliferative when treated with TRAIL (20 ng/ml) or several indirubin derivatives alone,

e.g. **9c**, **9f** at 1.25 μM and **9e**, **9i**, **9m**, **9k** at 2.5 μM . Inhibition by these indirubin derivatives alone ranged between 40% and 80% at a time point of 100 h (75 h after treatment). At this time, inhibition by TRAIL alone was at 60%. However upon combination treatments, cell proliferation and cell attachment was almost completely abolished for all tested indirubins. For **9d** and **9j**, an enhanced effect by combination treatment could not be clearly shown, as in this assay the effect of **9d** and **9j** alone was already very strong (Figure 5c).




Figure 5. Effects of *N*-glycosylated 3-(2-oxo-2-arylethylidene)indolin-2-ones on melanoma cells: (a) Cell viability of A-375 cells was determined after 24 h by calcein staining. Cells were treated with TRAIL (20 ng/ml), compounds of the series **9** (10 μM) or with combinations. (b) Cell proliferation of A-375 cells expressed as percent of non-treated controls was determined after 48 h by WST-1 assay. Cells were treated with 1.25 μM of compounds of series **9** and/or 20 ng/ml TRAIL. (c) Real-time cell analysis (RTCA) of A-375 cells treated with 1.25 μM / 2.5 μM of **9c**, **9d**, **9e**, **9f**, **9i**, **9m**, **9j** and **9k** +/- 20 ng/ml TRAIL. Seeding density was 1,250 cells per microtiter well. The cell index was normalized at 24 h,

when treatment was started. Cell indices indicate cell adhesion. (a - c) Each two independent experiments with triplicate determinations revealed highly comparable results.

As reported previously, treatment of melanoma cells with glycosylated indirubin analogs resulted in an inhibition of the phosphorylation of the transcription factor c-Jun.^{8c} This may be due to a direct inhibition of its upstream kinases c-Jun N-terminal kinases 1/2 (JNK1/2). To further address this question, SK-Mel-147 cells were treated with derivative **9b** and c-Jun phosphorylation was determined by immunoblotting. As treatment with 10 μ M of **9b** was associated with significant induction of cell death, lower concentrations were used (5 μ M, 6.5 μ M and 7.5 μ M). Inhibited c-Jun phosphorylation was seen for all three concentrations, and strongest effects were obtained with 6.5 μ M (Figure 6). The three concentrations also induced upregulation of p53 levels, which may support apoptosis induction in melanoma cells via p53-dependent pathways.




Figure 6. Derivative **9b** suppresses c-Jun phosphorylation in melanoma cells. SK-Mel-147 melanoma cells were treated for indicated times with 6.5 μ M of **9b**. Total protein lysates of cells were subjected to immunoblotting using specific antibodies for phosphorylated c-Jun (Ser63/73) and total p53. Staining for GAPDH was used as loading control.

To test whether inhibition of c-Jun phosphorylation was due to a direct inhibitory effect on the upstream kinases JNK1/2, ATP-competitive kinase binding assays were performed *in vitro* using recombinant JNK2 kinase. The small molecule inhibitor sorafenib, a well-known multi-

kinase inhibitor which strongly inhibits JNK1/2 kinases, was used as positive control. The IC₅₀ of sorafenib for the inhibition of JNK2 was determined at 1.6 μ M, whereas the IC₅₀ of **9b** was at 1.06 μ M. As negative control, the indirubin derivative **10** (Figure 7)⁷ was used, which did not inhibit the activity of JNK2 (figure 8).




Figure 7. Structure of the *N*- β -L-rhamnopyranosylindirubin **10** used as control substance.

Thus, it could be demonstrated that derivative **9b** exerted a strong inhibitory effect on JNK2, which explains its inhibitory activity on c-Jun phosphorylation. Suppression of JNK2 and c-Jun may significantly contribute to the decreased proliferation and enhanced apoptosis sensitivity of melanoma cells after treatment with derivative **9b**, as c-Jun plays a decisive role in melanoma cell proliferation and survival.




Figure 8. Derivative **9b** strongly inhibits JNK2 activity in melanoma cells. Kinase ATP-binding assays were performed with recombinant JNK2 using different concentrations of the positive control inhibitor sorafenib as well as of derivatives **9b** and **10**. Experiments were performed three times each in triplicates. IC_{50} values were calculated after analysis of all experiments. Graphs correspond to the means of one representative experiment.

Conclusions

In conclusion, the first synthesis of acetyl protected *N*-glycosylated 3-(2-oxo-2-arylethylidene)indolin-2-ones was reported. The synthesis relies on the aldol condensation of readily available isatin-*N*-glycosides with substituted acetophenones. The preparation of the corresponding deprotected derivatives failed in most of the cases, probably due to the preferred formation of products of the retroaldol reaction. However, the protected derivatives showed interesting pharmacological activities, such as a significant decrease of cell viability and inhibition of cell proliferation. The effects were stronger in combination with the proapoptotic death ligand TRAIL (TNF-related apoptosis-inducing ligand). A reduction of the

cell viability by up to 90% and complete abrogation of cell proliferation are strongly suggestive for testing therapeutic strategies. With regard to our investigations related to the mode of antitumor activity of indirubin derivatives in the cell, our present study suggests that the investigated derivatives affected the prosurvival pathway of JNK and c-Jun.

Experimental section

Material and methods for the syntheses and characterisation of the new compounds

All solvents were anhydrous and commercially available and all reactions were performed under argon atmosphere. The synthesis of *N*-glycosylated isatin derivatives has been described in the literature.^{6b,7b,10} The substituted acetophenones were commercially available. Yields refer to isolated products. ¹H NMR spectra (250.13 MHz, 300.13 MHz and 500.13 MHz) and ¹³C NMR spectra (62.9 MHz, 75.5 MHz and 125.8 MHz) were recorded on Bruker spectrometers AV 250, AV 300 and AV 500 in CDCl₃ and DMSO-*d*₆ as solvents. The calibration of spectra was carried out on solvent signals (CDCl₃: δ (¹H) = 7.25, δ (¹³C) = 77.0; acetone-*d*₆: δ (¹H) = 2.05, δ (¹³C) = 29.83). For the NMR signals of the compounds **8a,b** and **9a-m** the atom labelling given in Figure 3 was used. Mass spectrometric data (MS) were obtained by electron ionization (EI, 70 eV), chemical ionization (CI, isobutane) or electrospray ionization (ESI). The mass spectra and high-resolution mass spectra (HRMS) were recorded on the following MS instruments: Time-of-Flight (LC / MS 6210 (Agilent Technologies) for ESI and Finnigan MAT 95 XP (Thermo Electron Corporation) for EI / CI. Elemental analyses were performed on a C,H,N,S analyser (Thermo Quest Flash EA 1112). The melting points were measured with a polarizing microscope (Leitz Laborlux 12 Pol-S) equipped with a hot stage (Mettler FP 90). Thin layer chromatography was performed on silica-gel foil (Merck DC-foil, silica gel 60, F₂₅₄) and silica gel plates (Merck HPTLC precoated plates, silica gel 60, F₂₅₄) pursues. Detection was carried out via UV absorbance at 254 nm or 366 nm and/or development with 10% methanolic sulfuric acid and subsequent heat treatment. Column chromatography was performed on Macherey-Nagel silica gel 60 (particle size 63-200 nm, 70-230 mesh).

General procedure for the synthesis of the intermediate addition products **8** and aldolcondensation products **9**

1 Eq. of the *N*-glycosylisatin and 2 eq. of the substituted acetophenone are dissolved in abs. ethanol (4-8 ml per mmol *N*-glycosylisatin) (in the case of the unsubstituted acetophenone as reactant, this was used as the solvent in excess and no ethanol was used). To this solution, 1-2 eq. of triethylamine are added and the mixture is stirred for 6-12 hours at room temperature. After complete conversion of the starting material (TLC control), the reaction mixture is diluted with toluene and then evaporated under reduced pressure. The crude aldol addition products **8** can be directly used for the next step or (if containing larger amounts of by-products) can be purified by column chromatography (heptane : ethyl acetate, v:v = 3:1→2:1).

The crude or purified aldol addition product **8** (1 eq.) and 4-(dimethylamino)pyridine (1.1 eq.)* are dissolved in dry dichloromethane and the solution is cooled to 0 °C. Then triethylamine (1.1 eq.) (*in the cases where no DMAP was used, 2.2 eq. of NEt₃ were added) and methanesulfonyl chloride (1.1 eq.) are carefully added (syringe). After that, the cooling bath is removed and the mixture is allowed to warm to room temperature during 2 hours. After additional 6-8 hours stirring at room temperature (TLC control), the solution is diluted with dichloromethane and washed twice with saturated NaHCO₃ solution, 1M NaHSO₄ solution and brine, respectively. The organic layer is then dried over sodium sulfate, filtered and concentrated under diminished pressure. The residue is purified by column chromatography (heptane : ethyl acetate, v:v = 2:1) to give product **9**.

3-Hydroxy-3-(2-oxo-2-phenylethyl)-1-(2,3,4-tri-O-acetyl-β-L-rhamnopyranosyl)indolin-2-one
(**8a**)

According to the general procedure **7a** (200 mg, 0.48 mmol) was dissolved in about 1.5 ml acetophenone and triethylamine (67 μL, 0.48 mmol) was added to start the reaction. After work up **8a** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 6:1 → 3:1) as colourless amorphous solid (yield: 238 mg, 93 %) which consists of a diastereomeric mixture (diastereomer 1: diastereomer 2 = 4:1) due to the new formed chiral center at C-3. R_f 0.15 (heptane/ ethyl acetate, v:v = 3:1).

¹H NMR (250 MHz, CDCl₃): diastereomer 1: δ = 7.87 (d, ³J_{o,m} = 7.9 Hz, 2H, 2H_{ortho}), 7.54 ("t", ³J_{m,p} = 7.6 Hz, 1H, H_{para}), 7.53 (d, ³J_{7,6} = 7.5 Hz, 1H, H-7), 7.41 ("t", ³J_{o,m} ≈ ³J_{m,p} ≈ 7.8 Hz, 2H, 2H_{meta}), 7.32 (d, ³J_{4,5} = 7.5 Hz, 1H, H-4), 7.23 ("t", ³J_{6,7} ≈ ³J_{6,5} ≈ 7.6 Hz, 1H, H-6),

6.98 (“t”, $^3J_{5,4} \approx ^3J_{5,6} \approx 7.6$ Hz, 1H, H-5), 5.85 (d, $^3J_{1',2'} = 1.5$ Hz, H-1'), 5.59 (dd, $^3J_{2',1'} = 1.5$ Hz, $^3J_{2',3'} = 3.0$ Hz, 1H, H-2'), 5.26-5.21 (m, 2H, H-3', H-4'), 3.79 (s, 1H, OH), 3.78-3.66 (m, 1H, H-5'), 3.71 (d, $^2J_{8a,8b} = 17.2$ Hz, 1H, H-8a), 3.42 (d, $^2J_{8a,8b} = 17.2$ Hz, 1H, H-8b), 2.08, 1.98, 1.77 (3s, 9H, 3CH₃CO), 1.35 (d, $^3J_{5',6'} = 6.2$ Hz, 3H, 3H-6'). diastereomer 2 (minor): δ = 7.87 (d, $^3J_{o,m} = 7.9$ Hz, 2H, 2H_{ortho}), 7.54 (“t”, $^3J_{m,p} = 7.6$ Hz, 1H, H_{para}), 7.53 (d, $^3J_{7,6} = 7.5$ Hz, 1H, H-7), 7.41 (“t”, $^3J_{o,m} \approx ^3J_{m,p} \approx 7.8$ Hz, 2H, 2H_{meta}), 7.32 (d, $^3J_{4,5} = 7.5$ Hz, 1H, H-4), 7.23 (“t”, $^3J_{6,7} \approx ^3J_{6,5} \approx 7.6$ Hz, 1H, H-6), 6.98 (“t”, $^3J_{5,4} \approx ^3J_{5,6} \approx 7.6$ Hz, 1H, H-5), 5.87 (d, $^3J_{1',2'} = 1.4$ Hz, H-1'), 5.59 (dd, $^3J_{1',2'} = 1.4$ Hz, $^3J_{2',3'} = 3.0$ Hz, 1H, H-2'), 5.26-5.21 (m, 2H, H-3', H-4'), 4.12 (d, $^2J_{8a,8b} = 14.1$ Hz, 1H, H-8a), 4.08 (d, $^2J_{8a,8b} = 14.1$ Hz, 1H, H-8b), 3.79 (s, 1H, OH), 3.78-3.66 (m, 1H, H-5'), 2.08, 1.98, 1.68 (3s, 9H, 3CH₃CO), 1.40 (d, $^3J_{5',6'} = 6.2$ Hz, 3H, 3H-6'). **¹³C NMR (75 MHz, CDCl₃):** diastereomer 1: δ = 198.5 (C-9), 175.3 (C-2), 170.1, 170.0, 169.7 (3CH₃C=O), 141.0 (C-7a), 136.3 (C_{ipso}), 133.8 (C_{para}), 129.9 (C-3a), 129.2 (C-6), 128.7 (2C_{meta}), 128.3 (2C_{ortho}), 123.5 (C-4), 123.1 (C-5), 114.2 (C-7), 80.7 (C-1'), 74.3 (C-3), 73.9 (C-5'), 70.5 (C-2'), 70.4 (C-3'), 70.3 (C-4'), 44.2 (C-8), 20.9, 20.8, 20.6 (3CH₃CO), 17.7 (C-6'). diastereomer 2 (minor): δ = 196.8 (C-9), 175.7 (C-2), 171.1, 170.0, 169.6 (3CH₃C=O), 141.5 (C-7a), 136.1 (C_{ipso}), 133.6 (C_{para}), 130.1 (C-3a), 129.4 (C-6), 128.6 (2C_{meta}), 128.1 (2C_{ortho}), 123.3 (C-4), 123.1 (C-5), 114.0 (C-7), 81.2 (C-1'), 74.0 (C-3), 73.6 (C-5'), 70.4 (C-2'), 70.3 (C-3'), 70.1 (C-4'), 44.8 (C-8), 20.9, 20.8, 20.6 (3CH₃CO), 17.7 (C-6'). **HRMS (ESI):** calc. for C₂₈H₃₀NO₁₀ ([M+H]⁺) 540.18642, found 540.18695.

3-Hydroxy-3-(2-(4-methoxyphenyl)-2-oxoethyl)-1-(2,3,4-tri-O-acetyl- β -L-rhamnopyranosyl)indolin-2-one (8b)

According to the general procedure **7a** (200 mg, 0.48 mmol) and 4-methoxyacetophenone (144 mg, 0.96 mmol) were dissolved in about 1.5 ml of ethanol. Then triethylamine (67 μ L, 0.48 mmol) was added to start the reaction. After work up **8b** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 6:1 \rightarrow 3:1) as colourless amorphous solid (yield: 260 mg, 95 %) which consists of a diastereomeric mixture (diastereomer 1: diastereomer 2 = 3:1) due to the new formed chiral center at C-3. *R_f* 0.22 (heptane/ ethyl acetate, v:v = 3:1).

¹H-NMR (250 MHz, CDCl₃): diastereomer 1: δ = 7.91-7.83 (m, $^3J_{o,m} = 7.9$ Hz, 2H, 2H_{ortho}), 7.50 (d, $^3J_{7,6} = 7.9$ Hz, 1H, H-7), 7.32 (d, $^3J_{4,5} = 7.6$ Hz, 1H, H-4), 7.22 (“dt”, $^4J_{6,4} = 1.2$ Hz, $^3J_{6,7} \approx ^3J_{6,5} \approx 7.8$ Hz, 1H, H-6), 6.98 (“dt”, $^4J_{5,7} = 1.3$ Hz, $^3J_{5,4} \approx ^3J_{5,6} \approx 7.6$ Hz, 1H, H-5), 6.88 (“d”, $^3J_{o,m} = 7.8$ Hz, 2H, 2H_{meta}), 5.83 (d, $^3J_{1',2'} = 1.4$ Hz, H-1'), 5.58 (dd, $^3J_{1',2'} = 1.5$ Hz,

$^3J_{2',3'} = 3.0$ Hz, 1H, H-2'), 5.25-5.20 (m, 2H, H-3', H-4'), 5.00 (s, 1H, OH), 3.83 (s, 3H, OCH₃), 3.77-3.69 (m, 1H, H-5'), 3.59 (d, $^2J_{8a,8b} = 16.8$ Hz, 1H, H-8a), 3.29 (d, $^2J_{8a,8b} = 16.8$ Hz, 1H, H-8b), 2.08, 1.98, 1.76 (3s, 9H, 3CH₃CO), 1.35 (d, $^3J_{5',6'} = 6.2$ Hz, 3H, 3H-6'). diastereomer 2 (minor): $\delta = 7.91$ -7.83 (m, $^3J_{o,m} = 7.9$ Hz, 2H, 2H_{ortho}), 7.50 (d, $^3J_{7,6} = 8.0$ Hz, 1H, H-7), 7.32 (d, $^3J_{4,5} = 7.6$ Hz, 1H, H-4), 7.22 ("dt", $^4J_{6,4} = 1.2$ Hz, $^3J_{6,7} \approx ^3J_{6,5} \approx 7.8$ Hz, 1H, H-6), 6.98 ("dt", $^4J_{5,7} = 1.3$ Hz, $^3J_{5,4} \approx ^3J_{5,6} \approx 7.6$ Hz, 1H, H-5), 6.88 ("d", $^3J_{o,m} = 7.8$ Hz, 2H, 2H_{meta}), 5.86 (d, $^3J_{1',2'} = 1.4$ Hz, H-1'), 5.58 (dd, $^3J_{1',2'} = 1.5$ Hz, $^3J_{2',3'} = 3.0$ Hz, 1H, H-2'), 5.25-5.20 (m, 2H, H-3', H-4'), 4.12 (d, $^2J_{8a,8b} = 14.4$ Hz, 1H, H-8a), 4.09 (d, $^2J_{8a,8b} = 14.4$ Hz, 1H, H-8b), 4.03 (s, 1H, OH), 3.83 (s, 3H, OCH₃), 3.77-3.69 (m, 1H, H-5'), 2.08, 1.97, 1.69 (3s, 9H, 3CH₃CO), 1.39 (d, $^3J_{5',6'} = 6.2$ Hz, 3H, 3H-6'). **¹³C-NMR (75 MHz, CDCl₃):** diastereomer 1: $\delta = 197.4$ (C-9), 175.3 (C-2), 170.2, 170.0, 169.6 (3CH₃C=O), 164.1 (C_{para}), 140.8 (C-7a), 130.8 (2C_{meta}), 130.1 (C_{ipso}), 129.5 (C-3a), 129.1 (C-6), 123.6 (C-4), 123.1 (C-5), 113.9 (2C_{ortho}), 113.8 (C-7), 80.6 (C-1'), 74.5 (C-3), 73.9 (C-5'), 70.5 (C-2'), 70.4 (C-3'), 70.3 (C-4'), 55.5 (OCH₃), 43.2 (C-8), 20.8, 20.7, 20.5 (3CH₃CO), 17.7 (C-6'). diastereomer 2 (minor): $\delta = 195.5$ (C-9), 175.7 (C-2), 170.0, 170.0, 169.6 (3CH₃C=O), 163.9 (C_{para}), 141.4 (C-7a), 130.6 (2C_{meta}), 130.3 (C_{ipso}), 129.3 (C-3a), 129.3 (C-6), 123.3 (C-4), 123.1 (C-5), 113.8 (2C_{ortho}), 113.6 (C-7), 81.1 (C-1'), 73.9 (C-5'), 73.8 (C-3), 70.4 (C-2'), 70.4 (C-3'), 70.1 (C-4'), 55.5 (OCH₃), 44.2 (C-8), 20.7, 20.6, 20.5 (3CH₃CO), 17.7 (C-6'). **MS (EI, 70eV): m/z (%) = 569 (M⁺, 1), 551 (4), 273 (45), 171 (15), 153 (53).** **HRMS (ESI):** calc. for C₂₉H₃₂NO₁₁ ([M+H]⁺) 570.19699, found 570.19621.

(E)-3-(2-Oxo-2-phenylethylidene)-1-(2,3,4-tri-O-acetyl-β-L-rhamnopyranosyl)indolin-2-one
(**9a**)

According to the general procedure purified **8a** (200 mg, 0.37 mmol) and 4-(dimethylamino)pyridine (50 mg, 0.41 mmol) were dissolved in about 2 ml of dichloromethane. Then triethylamine (57 μl, 0.41 mmol) and methanesulfonyl chloride (32 μl, 0.41 mmol) were added carefully to the reaction mixture. After work up **9a** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 6:1 → 3:1) as orange solid (yield: 137 mg, 71 %). mp 74-76 °C (heptane/ ethyl acetate).

¹H-NMR (300 MHz, CDCl₃): $\delta = 8.22$ (d, $^3J_{4,5} = 7.9$ Hz, 1H, H-4), 8.08-8.05 (m, 2H, 2H_{ortho}), 7.83 (s, 1H, H-8), 7.61 ("t", $^3J = 7.8$ Hz, 2H, 2H_{meta}), 7.53-7.47 (m, 1H, H_{para}), 7.48 (d, $^3J_{7,6} = 7.6$ Hz, 1H, H-7), 7.30 ("dt", $^4J_{6,4} = 1.2$ Hz, $^3J_{6,7} \approx ^3J_{6,5} \approx 7.6$ Hz, 1H, H-6), 6.98 ("dt", $^4J_{5,7} = 1.2$ Hz, $^3J_{5,4} \approx ^3J_{5,6} \approx 7.8$ Hz, 1H, H-5), 5.94 (d, $^3J_{1',2'} = 1.4$ Hz, H-1'), 5.59 (dd, $^3J_{1',2'} = 1.5$

Hz, $^3J_{2,3'} = 3.0$ Hz, 1H, H-2'), 5.29-5.17 (m, $^3J_{2,3'} = 3.0$ Hz, $^3J_{3,4'} = 10.1$ Hz, 2H, H-3', H-4'), 3.80-3.71 (m, $^3J_{5,6'} = 6.1$ Hz, $^3J_{4',5'} = 9.4$ Hz, 1H, H-5'), 2.09, 1.97, 1.84 (3s, 9H, 3CH₃CO), 1.35 (d, $^3J_{5,6'} = 6.2$ Hz, 3H, 3H-6'). ¹³C-NMR (75 MHz, CDCl₃): δ = 191.1 (C-9), 169.9, 169.7, 169.6 (3CH₃C=O), 166.9 (C-2), 143.2 (C-3), 137.4 (C_{ipso}), 135.2 (C-7a), 133.9 (C_{para}), 131.9 (C-6), 128.9 (2C_{meta}), 128.8 (2C_{ortho}), 127.2 (C-8), 127.1 (C-4), 122.9 (C-5), 120.2 (C-3a), 113.9 (C-7), 80.4 (C-1'), 74.0 (C-5'), 70.6 (C-3'), 70.4 (C-2'), 70.1 (C-4'), 20.8, 20.7, 20.5 (3CH₃CO), 17.6 (C-6'). MS (EI, 70 eV): m/z (%) = 521 (M⁺, 12), 273 (24), 153 (59). HRMS (ESI): calc. for C₂₈H₂₇NNaO₉ ([M+Na]⁺) 544.15780, found 544.15760.

(E)-3-(2-(4-Methoxyphenyl)-2-oxoethylidene)-1-(2,3,4-tri-O-acetyl-β-L-rhamnopyranosyl)indolin-2-one (9b)

According to the general procedure purified **8b** (210 mg, 0.37 mmol) and 4-(dimethylamino)pyridine (50 mg, 0.41 mmol) were dissolved in about 2 ml of dichloromethane. Then triethylamine (57 μl, 0.41 mmol) and methanesulfonyl chloride (32 μl, 0.41 mmol) were added carefully to the reaction mixture. After work up **9b** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 6:1 → 3:1) as orange solid (yield: 163 mg, 80 %). mp 87-90 °C (heptane/ ethyl acetate). *R_f* 0.45 (heptane/ ethyl acetate, v:v = 1:3).

¹H-NMR (300 MHz, CDCl₃): δ = 8.14 (d, $^3J_{4,5} = 7.9$ Hz, 1H, H-4), 8.06 (d, $^3J_{o,m} = 8.9$ Hz, 2H, 2H_{ortho}), 7.83 (s, 1H, H-8), 6.97 (d, $^3J_{o,m} = 8.9$ Hz, 2H, 2H_{meta}), 7.50 (d, $^3J_{7,6} = 7.9$ Hz, 1H, H-7), 7.30 ("dt", $^4J_{6,4} = 1.2$ Hz, $^3J_{6,5} \approx ^3J_{5,6} \approx 7.7$ Hz, 1H, H-6), 6.98 ("dt", $^4J_{5,7} = 1.2$ Hz, $^3J_{5,4} \approx ^3J_{5,6} \approx 7.8$ Hz, 1H, H-5), 5.94 (d, $^3J_{1',2'} = 1.4$ Hz, 1H, H-1'), 5.59 (dd, $^3J_{1',2'} = 1.5$ Hz, $^3J_{2',3'} = 3.0$ Hz, 1H, H-2'), 5.29-5.17 (m, $^3J_{2',3'} = 3.0$ Hz, $^3J_{3',4'} = 10.1$ Hz, 2H, H-3', H-4'), 3.88 (s, 3H, OCH₃), 3.80-3.71 (m, $^3J_{5',6'} = 6.1$ Hz, $^3J_{4',5'} = 9.4$ Hz, 1H, H-5'), 2.09, 1.97, 1.84 (3s, 9H, 3CH₃CO), 1.35 (d, $^3J_{5',6'} = 6.2$ Hz, 3H, 3H-6'). ¹³C-NMR (75 MHz, CDCl₃): δ = 189.6 (C-9), 169.9, 169.7, 169.6 (3CH₃C=O) 167.0 (C-2), 164.3 (C_{para}), 142.9 (C-3), 134.3 (C_{ipso}), 135.2 (C-7a), 131.5 (C-6), 131.3 (2C_{meta}), 128.0 (C-8), 126.9 (C-4), 122.9 (C-5), 120.3 (C-3a), 114.1 (2C_{ortho}), 113.8 (C-7), 80.4 (C-1'), 74.0 (C-5'), 70.6 (C-3'), 70.4 (C-2'), 70.1 (C-4'), 55.6 (OCH₃), 20.8, 20.8, 20.5 (3CH₃CO), 17.6 (C-6'). MS (EI, 70 eV): m/z (%) = 551 (M⁺, 30), 273 ([M-aglycone]⁺, 61), 153 (100). HRMS (EI): calc. for C₂₉H₂₉NO₁₀ (M⁺) 551.17860, found 551.17748.

(E)-3-(2-(4-Nitrophenyl)-2-oxoethylidene)-1-(2,3,4-tri-O-acetyl- β -L-rhamnopyranosyl)indolin-2-one (9c)

According to the general procedure **7a** (200 mg, 0.48 mmol) and 4-nitroacetophenone (159 mg, 0.96 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (97 mg, 0.96 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (97 mg, 0.96 mmol) and methanesulfonyl chloride (110 mg, 0.96 mmol). After work up **9c** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 212 mg, 78 %). mp 160-161°C (heptane/ ethyl acetate).

^1H NMR (300 MHz, CDCl_3): δ = 8.39 (d (br, overlapped), 1H, H-4), 8.36 (d, $^3J_{\text{o,m}}$ = 8.9 Hz, 2H, 2H_{meta}), 8.23 (d, $^3J_{\text{o,m}}$ = 8.9 Hz, 2H, 2H_{ortho}), 7.80 (s, 1H, H-8), 7.53 (d (br), $^3J_{7,6}$ = 8.1 Hz, 1H, H-7), 7.36 ("dt", $^4J_{6,4}$ = 1.2 Hz, $^3J_{6,7} \approx ^3J_{6,5} \approx 8.0$ Hz, 1H, H-6), 7.03 ("dt", $^4J_{5,7}$ = 1.0 Hz, $^3J_{5,4} \approx ^3J_{5,6} \approx 7.7$ Hz, 1H, H-5), 5.92 (d, $^3J_{1',2'}$ = 1.5 Hz, 1H, H-1'), 5.59 (dd, $^3J_{2',1'}$ = 1.5 Hz, $^3J_{2',3'}$ = 3.0 Hz, 1H, H-2'), 5.30-5.18 (m, 2H, H-3', H-4'), 3.82-3.71 (m, 1H, H-5'), 2.09, 1.98, 1.84 (3s, 9H, 3CH₃CO), 1.36 (d, $^3J_{5',6'}$ = 6.2 Hz, 3H, 3H-6'). ^{13}C NMR (63 MHz, CDCl_3): δ = 189.1 (C-9), 170.0, 169.7, 169.7 (3CH₃C=O), 166.7 (C-2), 150.6, 143.9, 142.1, 137.2 (4C), 132.9 (CH), 129.7 (2CH), 127.7, 124.6 (2CH), 124.1 (2CH), 123.2 (CH), 120.0 (C), 114.1 (CH), 80.6, 74.1, 70.5, 70.3, 70.1 (C-1', C-2', C-3', C-4', C-5'), 20.8, 20.8, 20.5 (3CH₃CO), 17.7 (C-6'). MS (EI, 70eV): m/z (%) = 556 (M^+ , 12), 294 (9), 273 (63), 153 (80), 111 (72). HRMS (ESI): calc. for $\text{C}_{28}\text{H}_{27}\text{N}_2\text{O}_{11}$ ($[\text{M}+\text{H}]^+$) 567.16094 and for $\text{C}_{28}\text{H}_{26}\text{N}_2\text{NaO}_{11}$ ($[\text{M}+\text{Na}]^+$) 589.14288, found 567.16135 and 589.14317.

(E)-3-(2-(4-Chlorophenyl)-2-oxoethylidene)-1-(2,3,4-tri-O-acetyl- β -L-rhamnopyranosyl)indolin-2-one (9d)

According to the general procedure **7a** (200 mg, 0.48 mmol) and 4-chloroacetophenone (149 mg, 0.96 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (97 mg, 0.96 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (97 mg, 0.96 mmol) and methanesulfonyl chloride (110 mg, 0.96 mmol). After work up **9d** could be isolated after

column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 131 mg, 49 %). mp 160-162°C (heptane/ ethyl acetate).

^1H NMR (300 MHz, CDCl_3): δ = 8.24 (d (br), $^3J_{4,5}$ = 7.9 Hz, 1H, H-4), 8.02 ("d", 2H, $^3J_{o,m}$ = 8.6 Hz, 2H_{ortho}), 7.78 (s, 1H, H-8), 7.51 (d (br, overlapped), 1H, H-7), 7.49 ("d", 2H, $^3J_{o,m}$ = 8.6 Hz, 2H_{meta}), 7.32 ("dt", $^4J_{6,4}$ = 1.3 Hz, $^3J_{6,7} \approx ^3J_{6,5} \approx 7.9$ Hz, 1H, H-6), 7.00 ("dt", $^4J_{5,7}$ = 1.0 Hz, $^3J_{4,5} \approx ^3J_{5,6} \approx 7.8$ Hz, 1H, H-5), 5.93 (d, $^3J_{1',2'}$ = 1.5 Hz, 1H, H-1'), 5.59 (dd, $^3J_{2',1'}$ = 1.5 Hz, $^3J_{2',3'}$ = 3.0 Hz, 1H, H-2'), 5.29-5.17 (m, 2H, H-3', H-4'), 3.81-3.71 (m, 1H, H-5'), 2.08, 1.96, 1.82 (3s, 9H, 3CH₃CO), 1.34 (d, $^3J_{5',6'}$ = 6.2 Hz, 3H, 3H-6'). ^{13}C NMR (75 MHz, CDCl_3): δ = 189.6 (C-9), 169.8, 169.6, 169.6 (3CH₃C=O), 166.7 (C-2) 143.3, 140.3, 135.7, 135.6 (4C), 132.0 (CH), 130.1 (2CH), 129.1 (2CH), 127.1 (CH), 126.1 (CH), 122.9 (CH), 120.0 (C), 113.8 (CH), 80.4, 73.9, 70.5, 70.2, 70.0 (C-1', C-2', C-3', C-4', C-5'), 20.6, 20.6, 20.4 (3CH₃CO), 17.5 (C-6'). MS (EI, 70 eV): m/z (%) = 555 (M^+ [^{35}Cl], 22), 557 (M^+ [^{37}Cl], 11), 312 (9), 283 (13), 273 (70), 153 (89), 111 (84). HRMS (ESI): calc. for $\text{C}_{28}\text{H}_{27}^{35}\text{ClNO}_9$ ($[\text{M}+\text{H}]^+$) 556.13689 and for $\text{C}_{28}\text{H}_{26}^{35}\text{ClNaNO}_9$ ($[\text{M}+\text{Na}]^+$) 578.11883, found 556.13773 and 578.11996.

(E)-3-(2-(4-Fluorophenyl)-2-oxoethylidene)-1-(2,3,4-tri-O-acetyl- β -L-rhamnopyranosyl)indolin-2-one (9e)

According to the general procedure **7a** (200 mg, 0.48 mmol) and 4-fluoroacetophenone (133 mg, 0.96 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (97 mg, 0.96 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (97 mg, 0.96 mmol) and methanesulfonyl chloride (110 mg, 0.96 mmol). After work up **9e** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 168 mg, 65 %). mp 200-202°C (heptane/ ethyl acetate).

^1H NMR (300 MHz, CDCl_3): δ = 8.21 (d (br), $^3J_{4,5}$ = 7.8 Hz, 1H, H-4), 8.11 ("dd", 2H, $^3J_{o,m}$ = 8.9 Hz, $^4J_{o,F}$ = 5.3 Hz, 2H_{ortho}), 7.79 (s, 1H, H-8), 7.51 (d (br), $^3J_{6,7}$ = 8.1 Hz, 1H, H-7), 7.31 ("dt", $^4J_{6,4}$ = 1.3 Hz, $^3J_{6,7} \approx ^3J_{6,5} \approx 7.9$ Hz, 1H, H-6), 7.19 ("t", 2H, $^3J_{o,m} \approx ^3J_{m,F} \approx 8.6$ Hz, 2H_{meta}), 6.99 ("dt", $^4J_{5,7}$ = 1.0 Hz, $^3J_{5,4} \approx ^3J_{5,6} \approx 7.7$ Hz, 1H, H-5), 5.93 (d, $^3J_{1',2'}$ = 1.5 Hz, 1H, H-1'), 5.60 (dd, $^3J_{2',1'}$ = 1.5 Hz, $^3J_{2',3'}$ = 3.0 Hz, 1H, H-2'), 5.29-5.18 (m, 2H, H-3', H-4'), 3.81-3.72 (m, 1H, H-5'), 2.09, 1.98, 1.84 (3s, 9H, 3CH₃CO), 1.36 (d, $^3J_{5',6'}$ = 6.0 Hz, 3H, 3H-

6'). ^{13}C NMR (63 MHz, CDCl_3): δ = 189.4 (C-9), 169.9, 169.7, 169.7 ($3\text{CH}_3\text{CO}$), 166.9 (C-2), 165.5 (d, $^1J_{\text{C,F}}$ = 256.3 Hz, C_{para}), 143.2, 135.4 (2C), 133.9 (d, $^4J_{\text{C,F}}$ = 2.7 Hz, C_{ipso}), 132.0 (CH), 131.6 (d, $^3J_{\text{C,F}}$ = 9.6 Hz, $2\text{CH}_{\text{ortho}}$), 127.1, 126.6, 123.0 (3CH), 120.1 (C), 116.1 (d, $^2J_{\text{C,F}}$ = 22.0 Hz, 2CH_{meta}), 113.9 (CH), 80.4, 74.0, 70.5, 70.3, 70.1 (C-1', C-2', C-3', C-4', C-5'), 20.7, 20.7, 20.5 ($3\text{CH}_3\text{CO}$), 17.6 (C-6'). ^{19}F NMR (282 MHz, CDCl_3): δ = 103.34 (s, CF). MS (EI, 70eV): m/z (%) = 539 (M^+ , 22), 296 (10), 273 (66), 171 (24), 153 (90), 111 (75). HRMS (EI): calc. for $\text{C}_{28}\text{H}_{26}\text{FNO}_9$ (M^+) 539.15861, found 539.15921.

(E)-3-(2-(4-Nitrophenyl)-2-oxoethylidene)-1-(2,3,4,6-tetra-O-acetyl- β -D-mannopyranosyl)indolin-2-one (9f)

According to the general procedure **7b** (200 mg, 0.42 mmol) and 4-nitroacetophenone (139 mg, 0.84 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (43 mg, 0.84 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (43 mg, 0.84 mmol) and methanesulfonyl chloride (96 mg, 0.84 mmol). After work up **9f** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 184 mg, 70 %). mp 187-189 °C (heptane/ ethyl acetate).

^1H NMR (250 MHz, CDCl_3): δ = 8.41-8.34 (m, 3H, 2H_{meta} , H-4), 8.23 ("d", $^3J_{\text{o,m}}$ = 8.9 Hz, 2H, 2H_{ortho}), 7.81 (s, 1H, H-8), 7.50 (d (br), $^3J_{6,7}$ = 8.1 Hz, 1H, H-7), 7.35 ("dt", $^4J_{4,6}$ = 1.2 Hz, $^3J_{6,7} \approx ^3J_{5,6} \approx 7.9$ Hz, 1H, H-6), 7.04 ("dt", $^4J_{5,7}$ = 1.0 Hz, $^3J_{4,5} \approx ^3J_{5,6} \approx 7.7$ Hz, 1H, H-5), 5.97 (d, $^3J_{1',2'}$ = 1.5 Hz, 1H, H-1'), 5.61 (dd, $^3J_{2',1'}$ = 1.5 Hz, $^3J_{2',3'}$ = 3.3 Hz, 1H, H-2'), 5.46-5.28 (m, 2H, H-3', H-4'), 4.35-4.19 (m, 2H, $2\text{H}_{-6'}$), 3.93-3.86 (m, 1H, H-5'), 2.11, 2.09, 1.99, 1.84 (4s, 12H, $4\text{CH}_3\text{CO}$). ^{13}C NMR (63 MHz, CDCl_3): δ = 189.0 (C-9), 170.4, 169.7, 169.6, 169.6 ($4\text{CH}_3\text{CO}$), 166.7 (C-2), 150.5, 143.6, 142.0, 137.0 (4C), 132.8 (CH), 129.7 (2CH), 127.7, 124.7 (2CH), 124.1 (2CH), 123.2 (CH), 120.0 (C), 114.0 (CH), 80.6, 75.5, 70.5, 69.9, 65.2 (C-1', C-2', C-3', C-4', C-5'), 62.2 (C-6'), 20.7, 20.7, 20.6, 20.4 ($4\text{CH}_3\text{CO}$). MS (EI, 70eV): m/z (%) = 624 (M^+ , 20), 331 (66), 294 (13), 169 (94), 127 (19), 109 (73). HRMS (EI): calc. for $\text{C}_{30}\text{H}_{28}\text{N}_2\text{O}_{13}$ (M^+) 624.15859, found 624.16003.

(E)-3-(2-(4-Chlorophenyl)-2-oxoethylidene)-1-(2,3,4,6-tetra-O-acetyl- β -D-mannopyranosyl)indolin-2-one (9g)

According to the general procedure **7b** (200 mg, 0.42 mmol) and 4-chloroacetophenone (130 mg, 0.84 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (43 mg, 0.84 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (43 mg, 0.84 mmol) and methanesulfonyl chloride (96 mg, 0.84 mmol). After work up **9g** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 134 mg, 52 %). mp 80 - 82 °C (heptane/ ethyl acetate).

^1H NMR (300 MHz, CDCl_3): δ = 8.25 (d (br), $^3J_{4,5}$ = 7.9 Hz, 1H, H-4), 8.02 ("d", $^3J_{o,m}$ = 8.6 Hz, 2H, 2H_{ortho}), 7.79 (s, 1H, H-8), 7.47-7.52 (m, 3H, 2H_{meta} , H-7), 7.31 ("dt", $^4J_{4,6}$ = 1.3 Hz, $^3J_{6,7} \approx ^3J_{5,6} \approx 7.9$ Hz, 1H, H-6), 7.01 ("dt", $^4J_{5,7}$ = 1.0 Hz, $^3J_{4,5} \approx ^3J_{5,6} \approx 7.8$ Hz, 1H, H-5), 5.97 (d, $^3J_{1',2'}$ = 1.5 Hz, 1H, H-1'), 5.61 (dd, $^3J_{2',1'}$ = 1.5 Hz, $^3J_{2',3'}$ = 3.3 Hz, 1H, H-2'), 5.46-5.29 (m, 2H, H-3', H-4'), 4.34-4.20 (m, 2H, $2\text{H}-6'$), 3.92-3.86 (m, 1H, H-5'), 2.11, 2.09, 1.99, 1.84 (4s, 12H, $4\text{CH}_3\text{CO}$). ^{13}C NMR (63 MHz, CDCl_3): δ = 189.6 (C-9), 170.4, 169.6, 169.5, 169.5 ($4\text{CH}_3\text{CO}$), 166.8 (C-2), 143.2, 140.4, 135.7, 135.5 (4C), 132.0 (CH), 130.1 (2CH), 129.2 (2CH), 127.2, 126.3, 123.0 (3CH), 120.1 (C), 113.9 (CH), 80.5, 75.4, 70.5, 70.0, 65.3 (C-1', C-2', C-3', C-4', C-5'), 62.2 (C-6'), 20.7, 20.6, 20.6, 20.4 ($4\text{CH}_3\text{CO}$). MS (EI, 70eV): m/z (%) = 613 (M^+ [^{35}Cl], 20), 615 (M^+ [^{37}Cl], 11), 441 (12), 331 (35), 169 (100), 146 (13), 127 (12), 109 (36). HRMS (ESI): calc. for $\text{C}_{30}\text{H}_{29}^{35}\text{ClNO}_{11}$ ($[\text{M}+\text{H}]^+$) 614.14236 and for $\text{C}_{30}\text{H}_{28}^{35}\text{ClNaNO}_{11}$ ($[\text{M}+\text{Na}]^+$) 636.12431, found 614.14306 and 636.12571.

(E)-3-(2-(4-Fluorophenyl)-2-oxoethylidene)-1-(2,3,4,6-tetra-O-acetyl- β -D-mannopyranosyl)indolin-2-one (9h)

According to the general procedure **7b** (200 mg, 0.42 mmol) and 4-fluoroacetophenone (116 mg, 0.84 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (43 mg, 0.84 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (43 mg, 0.84 mmol) and methanesulfonyl chloride (96 mg, 0.84 mmol). After work up **9h** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 158 mg, 63 %). mp 158 - 160 °C (heptane/ ethyl acetate).

^1H NMR (300 MHz, CDCl_3): δ = 8.21 (d (br), $^3J_{4,5}$ = 7.8 Hz, 1H, H-4), 8.11 ("dd", 2H, $^3J_{o,m}$ = 8.9 Hz, $^4J_{o,F}$ = 5.4 Hz, 2H_{ortho}), 7.79 (s, 1H, H-8), 7.48 (d (br), $^3J_{6,7}$ = 8.1 Hz, 1H, H-7), 7.30

(“dt”, $^4J_{4,6} = 1.3$ Hz, $^3J_{6,7} \approx ^3J_{5,6} \approx 7.9$ Hz, 1H, H-6), 7.19 (“t”, 2H, $^3J_{o,m} \approx ^3J_{m,F} \approx 8.6$ Hz, 2H_{meta}), 7.00 (“dt”, $^4J_{5,7} = 1.0$ Hz, $^3J_{4,5} \approx ^3J_{5,6} \approx 7.7$ Hz, 1H, H-5), 5.97 (d, $^3J_{1',2'} = 1.5$ Hz, 1H, H-1'), 5.61 (dd, $^3J_{2',1'} = 1.5$ Hz, $^3J_{2',3'} = 3.3$ Hz, 1H, H-2'), 5.29-5.45 (m, 2H, H-3', H-4'), 4.34-4.20 (m, 2H, 2H-6'), 3.93-3.86 (m, 1H, H-5'), 2.11, 2.09, 1.98, 1.84 (4s, 12H, 4CH₃CO). ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.4$ (C-9), 170.5, 169.7, 169.6, 169.6 (4CH₃C=O), 166.9 (C-2), 166.3 (d, $^1J_{C,F} = 256.8$ Hz, C_{para}), 143.1, 135.3 (2C), 133.8 (d, $^4J_{C,F} = 2.8$ Hz, C_{ipso}), 132.0 (CH), 131.6 (d, $^3J_{C,F} = 9.5$ Hz, 2CH_{ortho}), 127.2, 126.8, 123.1 (3CH), 120.1 (C), 116.1 (d, $^2J_{C,F} = 22.1$ Hz, 2CH_{meta}), 113.9 (CH), 80.5, 75.5, 70.6, 70.0, 65.3 (C-1', C-2', C-3', C-4', C-5'), 62.2 (C-6'), 20.8, 20.7, 20.7, 20.5 (4CH₃CO). MS (EI, 70eV): m/z (%) = 597 (M⁺, 48), 331 (74), 296 (12), 267 (22), 239 (14), 211 (16), 169 (100), 123 (63), 109 (81). HRMS (EI): calc. for C₃₀H₂₈FNO₁₁ [M]⁺ 597.16409, found 597.16456.

(E)-3-(2-Oxo-2-(4-trifluoromethylphenyl)ethylidene)-1-(2,3,4,6-tetra-O-acetyl- β -D-mannopyranosyl)indolin-2-one (9i)

According to the general procedure **7b** (200 mg, 0.42 mmol) and 4-trifluoromethylacetophenone (158 mg, 0.84 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (43 mg, 0.84 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (43 mg, 0.84 mmol) and methanesulfonyl chloride (96 mg, 0.84 mmol). After work up **9i** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 188 mg, 69 %). mp 98 - 100 °C (heptane/ ethyl acetate).

¹H NMR (300 MHz, CDCl₃): $\delta = 8.34$ (d (br), $^3J_{4,5} = 7.8$ Hz, 1H, H-4), 8.18 (“d” (br), 2H, $^3J_{o,m} = 8.2$ Hz, 2H_{ortho}), 7.82 (s, 1H, H-8), 7.79 (“d” (br), 2H, $^3J_{o,m} = 8.2$ Hz, 2H_{meta}), 7.49 (d (br), $^3J_{6,7} = 8.1$ Hz, 1H, H-7), 7.33 (“dt”, $^4J_{4,6} = 1.3$ Hz, $^3J_{6,7} \approx ^3J_{5,6} \approx 7.9$ Hz, 1H, H-6), 7.03 (“dt”, $^4J_{5,7} = 1.0$ Hz, $^3J_{4,5} \approx ^3J_{5,6} \approx 7.8$ Hz, 1H, H-5), 5.97 (d, $^3J_{1',2'} = 1.5$ Hz, 1H, H-1'), 5.62 (dd, $^3J_{2',1'} = 1.5$ Hz, $^3J_{2',3'} = 3.3$ Hz, 1H, H-2'), 5.29-5.46 (m, 2H, H-3', H-4'), 4.20-4.35 (m, 2H, 2H-6'), 3.87-3.93 (m, 1H, H-5'), 2.11, 2.09, 1.99, 1.84 (4s, 12H, 4CH₃CO). ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.7$ (C-9), 170.4, 169.6, 169.6, 169.5 (4CH₃C=O), 166.7 (C-2), 143.4 (C), 140.1 (q, $^5J_{C,F} = 1.0$ Hz, C_{ipso}), 136.3 (C), 134.8 (q, $^2J_{C,F} = 32.7$ Hz, C_{para}), 132.4 (CH), 129.0 (2CH_{ortho}), 127.4 (CH), 125.8 (q, $^3J_{C,F} = 3.6$ Hz, 2CH_{meta}), 125.5 (CH), 123.5 (q, $^1J_{C,F} = 273.0$ Hz, CF₃), 123.1 (CH), 120.0 (C), 113.9 (CH), 80.5, 75.4, 70.5, 70.0, 65.2 (C-1', C-2', C-3', C-4', C-5'), 62.1 (C-6'), 20.7, 20.6, 20.6, 20.4 (4CH₃CO). ¹⁹F NMR (282 MHz, CDCl₃): $\delta =$

113.86 (s, CF₃). MS (EI, 70eV): *m/z* (%) = 647 (M⁺, 42), 331 (80), 317 (28), 289 (18), 173 (57), 169 (100), 145 (50), 127 (39), 109 (82). HRMS (EI): calc. for C₃₁H₂₈F₃NO₁₁ (M⁺) 647.16090, found 647.16114.

(E)-3-(2-(4-Nitrophenyl)-2-oxoethylidene)-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)indolin-2-one (9j)

According to the general procedure **7c** (200 mg, 0.42 mmol) and 4-nitroacetophenone (139 mg, 0.84 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (43 mg, 0.84 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (43 mg, 0.84 mmol) and methanesulfonyl chloride (96 mg, 0.84 mmol). After work up **9j** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 186 mg, 71 %). mp 205 - 207 °C (heptane/ ethyl acetate).

¹H NMR (300 MHz, acetone-d₆): δ = 8.37-8.47 (m, 4H, 2H_{meta}, 2H_{ortho}), 8.36 (d (br), ³J_{4,5} = 7.8 Hz, 1H, H-4), 7.88 (s, 1H, H-8), 7.60 (d (br), ³J_{7,6} = 8.0 Hz, 1H, H-7), 7.51 ("dt", ⁴J_{4,6} = 1.2 Hz, ³J_{6,7} ≈ ³J_{5,6} ≈ 7.8 Hz, 1H, H-6), 7.12 ("dt", ⁴J_{5,7} = 1.1 Hz, ³J_{4,5} ≈ ³J_{5,6} ≈ 7.7 Hz, 1H, H-5), 5.97 (d, ³J_{1',2'} = 9.4 Hz, 1H, H-1'), 5.72 ("t", ³J_{2',1'} ≈ ³J_{2',3'} ≈ 9.4 Hz, 1H, H-2'), 5.55 ("t", ³J_{4',3'} ≈ ³J_{4',5'} ≈ 9.5 Hz, 1H, H-4'), 5.36 ("t", ³J_{3',2'} ≈ ³J_{3',4'} ≈ 9.5 Hz, 1H, H-3'), 4.21-4.35 (m, 3H, H5', 2H-6'), 2.05, 2.04, 1.96, 1.83 (4s, 12H, 4CH₃CO). ¹³C NMR (63 MHz, acetone-d₆): δ = 190.6 (C-9), 170.7, 170.2, 170.1, 169.6 (4CH₃CO), 167.7 (C-2), 151.6, 144.0, 143.0, 137.2 (4C), 134.3 (CH), 130.9 (2CH), 128.2, 126.4 (2CH), 124.9 (2CH), 123.9 (CH), 120.8 (C), 113.5 (CH), 80.4, 75.2, 73.9, 68.9, 68.6 (C-1', C-2', C-3', C-4', C-5'), 62.7 (C-6'), 20.6, 20.6, 20.5, 20.2 (4CH₃CO). MS (EI, 70eV): *m/z* (%) = 624 (M⁺, 10), 331 (59), 294 (9), 169 (100), 150 (20), 127 (19), 109 (73). HRMS (EI): calc. for C₃₀H₂₈N₂O₁₃ (M⁺) 624.15859, found 624.15896.

(E)-3-(2-Oxo-2-(4-trifluoromethylphenyl)ethylidene)-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)indolin-2-one (9k)

According to the general procedure **7c** (200 mg, 0.42 mmol) and 4-trifluoromethylacetophenone (158 mg, 0.84 mmol) were dissolved in about 4 ml of ethanol.

Then triethylamine (43 mg, 0.84 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (43 mg, 0.84 mmol) and methanesulfonyl chloride (96 mg, 0.84 mmol). After work up **9k** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 182 mg, 67 %). mp 160 - 162 °C (heptane/ ethyl acetate).

¹H NMR (300 MHz, Aceton-d₆): δ = 8.28-8.32 (m, 3H, 2H_{ortho}, H-4), 7.93 ("d" (br), 2H, ³J_{o,m} = 8.2 Hz, 2H_{meta}), 7.84 (s, 1H, H-8), 7.56 (d (br), ³J_{7,6} = 8.0 Hz, 1H, H-7), 7.46 ("dt", ⁴J_{4,6} = 1.2 Hz, ³J_{6,7} ≈ ³J_{5,6} ≈ 7.8 Hz, 1H, H-6), 7.08 ("dt", ⁴J_{5,7} = 1.1 Hz, ³J_{4,5} ≈ ³J_{5,6} ≈ 7.7 Hz, 1H, H-5), 5.95 (d, ³J_{1',2'} = 9.4 Hz, 1H, H-1'), 5.70 ("t", ³J_{2',1'} ≈ ³J_{2',3'} ≈ 9.4 Hz, 1H, H-2'), 5.53 ("t", ³J_{4',3'} ≈ ³J_{4',5'} ≈ 9.5 Hz, 1H, H-4'), 5.33 ("t", ³J_{3',2'} ≈ ³J_{3',4'} ≈ 9.5 Hz, 1H, H-3'), 4.18-4.33 (m, 3H, H5', 2H-6'), 2.02, 2.01, 1.93, 1.80 (4s, 12H, 4CH₃CO). ¹³C NMR (63 MHz, Aceton-d₆): δ = 190.9 (C-9), 170.7, 170.2, 170.1, 169.6 (4CH₃CO), 167.8 (C-2), 143.9 (C), 141.5 (q, ⁵J_{C,F} = 1.1 Hz, C_{ipso}), 136.9 (C), 134.9 (q, ²J_{C,F} = 32.2 Hz, C_{para}), 134.1 (CH), 130.3 (2CH_{ortho}), 128.1 (CH), 126.9 (q, ³J_{C,F} = 3.7 Hz, 2CH_{meta}), 126.7 (CH), 124.9 (q, ¹J_{C,F} = 272.5 Hz, CF₃), 123.8 (CH), 120.8 (C), 113.5 (CH), 80.4, 75.1, 73.9, 68.9, 68.6 (C-1', C-2', C-3', C-4', C-5'), 62.7 (C-6'), 20.6, 20.6, 20.5, 20.2 (4CH₃CO). ¹⁹F NMR (282 MHz, acetone-d₆): δ = 113.86 (s, CF₃). MS (EI, 70eV): m/z (%) = 647 (M⁺, 14), 331 (55), 317 (13), 289 (8), 169 (100), 145 (23), 127 (21), 109 (81). HRMS (EI): calc. for C₃₁H₂₈F₃NO₁₁ (M⁺) 647.16090, found 647.16031.

(E)-3-(2-(4-Fluorophenyl)-2-oxoethylidene)-1-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)indolin-2-one (9l)

According to the general procedure **7d** (200 mg, 0.42 mmol) and 4-fluoroacetophenone (116 mg, 0.84 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (43 mg, 0.84 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (43 mg, 0.84 mmol) and methanesulfonyl chloride (96 mg, 0.84 mmol). After work up **9l** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 161 mg, 64 %).

¹H NMR (300 MHz, acetone-d₆): δ = 8.19-8.25 (m, 3H, 2H_{ortho}, H-4), 7.83 (s, 1H, H-8), 7.47-7.58 (m, 2H, H-6, H-7), 7.35 ("t", 2H, ³J_{o,m} ≈ ³J_{m,F} ≈ 8.8 Hz, 2H_{meta}), 7.10 ("dt", ⁴J_{5,7} = 1.4

Hz, $^3J_{4,5} \approx ^3J_{5,6} \approx 7.6$ Hz, 1H, H-5), 5.97 (d, $^3J_{1',2'} = 9.3$ Hz, 1H, H-1'), 5.82 ("t" (br), $^3J_{2',1'} \approx ^3J_{2',3'} \approx 9.6$ Hz, 1H, H-2'), 5.60 (dd, $^3J_{4',3'} = 3.2$ Hz, $^3J_{4',5'} = 0.8$ Hz, 1H, H-4'), 5.46 (dd, $^3J_{3',2'} = 10.0$ Hz, $^3J_{3',4'} = 3.2$ Hz, 1H, H-3'), 4.58 (ddd, $^3J_{5',4'} = 0.8$ Hz, $^3J_{5',6a'} = 5.6$ Hz, $^3J_{5',6b'} = 6.8$ Hz, 1H, H-5'), 4.29 (dd, $^3J_{6a',5'} = 5.6$ Hz, $^2J_{6a',6b'} = 11.5$ Hz, 1H, H-6a'), 4.14 (dd, $^3J_{6b',5'} = 6.8$ Hz, $^2J_{6b',6a'} = 11.5$ Hz, 1H, H-6b'), 2.31, 1.98, 1.95, 1.87 (4s, 12H, 4CH₃CO). ¹³C NMR (75 MHz, acetone-d₆): δ = 190.3 (C-9), 170.6, 170.5, 170.2, 169.8 (4CH₃C=O), 167.7 (C-2), 167.0 (d, $^1J_{C,F} = 254.2$ Hz, C_{para}), 143.7, 136.1 (2C), 135.1 (d, $^4J_{C,F} = 2.8$ Hz, C_{ipso}), 133.6, (CH), 132.6 (d, $^3J_{C,F} = 9.9$ Hz, 2CH_{ortho}), 127.9, 127.6, 123.7 (3CH), 120.9 (C), 116.9 (d, $^2J_{C,F} = 22.2$ Hz, 2CH_{meta}), 113.1 (CH), 80.5, 73.8, 72.0, 68.5, 66.4 (C-1', C-2', C-3', C-4', C-5'), 62.6 (C-6'), 20.7, 20.6, 20.5, 20.3 (4CH₃CO). ¹⁹F NMR (282 MHz, acetone-d₆): δ = 71.74 (s, CF). MS (EI, 70eV): m/z (%) = 597 (M⁺, 30), 331 (94), 317 (13), 289 (12), 211 (11), 169 (98), 146 (17), 127 (26), 123 (60), 109 (68). HRMS (ESI): calc. for C₃₀H₂₉FNO₁₁ ([M+H]⁺) 598.17192, found 598.17140.

(E)-3-(2-Oxo-2-(4-trifluoromethylphenyl)ethylidene)-1-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)indolin-2-one (9m)

According to the general procedure **7d** (200 mg, 0.42 mmol) and 4-trifluoromethylacetophenone (158 mg, 0.84 mmol) were dissolved in about 4 ml of ethanol. Then triethylamine (43 mg, 0.84 mmol) was added to start the reaction. After work up, the crude product was dissolved in about 4 ml of abs. dichloromethane and reacted with triethylamine (43 mg, 0.84 mmol) and methanesulfonyl chloride (96 mg, 0.84 mmol). After work up **9m** could be isolated after column chromatography (heptane/ ethyl acetate v:v = 3:1) as orange solid (yield: 180 mg, 66 %). mp 91 - 93 °C (heptane/ ethyl acetate).

¹H NMR (300 MHz, acetone-d₆): δ = 8.33-8.37 (m, 3H, 2H_{ortho}, H-4), 7.97 (d (br), $^3J_{o,m} = 8.2$ Hz, 2H, 2H_{meta}), 7.88 (s, 1H, H-8), 7.51-7.60 (m, 2H, H-6, H-7), 7.11-7.17 (m, 1H, H-5), 5.97 (d, $^3J_{1',2'} = 9.2$ Hz, 1H, H-1'), 5.82 ("t" (br), $^3J_{2',1'} \approx ^3J_{2',3'} \approx 9.6$ Hz, 1H, H-2'), 5.60 (dd, $^3J_{4',3'} = 3.3$ Hz, $^3J_{4',5'} = 0.9$ Hz, 1H, H-4'), 5.46 (dd, $^3J_{3',2'} = 10.0$ Hz, $^3J_{3',4'} = 3.3$ Hz, 1H, H-3'), 4.59 (ddd, $^3J_{5',4'} = 0.9$ Hz, $^3J_{5',6a'} = 5.7$ Hz, $^3J_{5',6b'} = 6.8$ Hz, 1H, H-5'), 4.29 (dd, $^3J_{6a',5'} = 5.7$ Hz, $^2J_{6a',6b'} = 11.5$ Hz, 1H, H-6a'), 4.15 (dd, $^3J_{6b',5'} = 6.8$ Hz, $^2J_{6b',6a'} = 11.5$ Hz, 1H, H-6b'), 2.32, 1.99, 1.96, 1.87 (4s, 12H, 4CH₃CO). ¹³C NMR (63 MHz, acetone-d₆): δ = 190.9 (C-9), 170.6, 170.5, 170.2, 169.8 (4CH₃C=O), 167.7 (C-2), 144.0, 141.5, 137.0 (3C), 134.9 (q, $^2J_{C,F} = 32.3$ Hz, C_{para}), 134.1 (CH), 130.3 (2CH_{ortho}), 128.2 (CH), 126.9 (q, $^3J_{C,F} = 3.8$ Hz, 2CH_{meta}),

126.7 (CH), 124.8 (q, $^1J_{C,F} = 272.0$ Hz, CF₃), 123.8 (CH), 120.9 (C), 113.2 (CH), 80.5, 73.8, 72.0, 68.5, 66.4 (C-1', C-2', C-3', C-4', C-5'), 62.6 (C-6'), 20.7, 20.6, 20.5, 20.3 (4CH₃CO). ¹⁹F NMR (282 MHz, CDCl₃): $\delta = 113.85$ (s, CF₃). MS (EI, 70eV): m/z (%) = 647 (M⁺, 18), 331 (96), 317 (16), 289 (13), 169 (96), 145 (20), 127 (20), 109 (56). HRMS (EI): calc. for C₃₁H₂₈F₃NO₁₁ (M⁺) 647.16090, found 647.16008.

Material and methods for the bioactivity tests

Melanoma cell lines and fibroblasts

Melanoma cell line SK-Mel-147 was kindly provided by M. Soengas, Department of Dermatology, University of Michigan, Ann Arbor, MI, USA. The melanoma cell line A-375 (CRL-1619), derived from ATCC (Maryland, MD, USA), is very well established for studying apoptosis in melanoma cells (15). Primary human dermal fibroblasts from healthy breast skin and foreskin were isolated using standard procedures and were kindly provided by U. Anderegg, Department of Dermatology, Venereology and Allergology, Medical Faculty, University of Leipzig.

IC50 assay

For determination of the half maximal inhibitory concentration (IC₅₀), cells were seeded in a 96-well-plate (4x10³ cells/well) and treated for 48 h with different concentrations of indirubin derivatives. Proliferation was analysed by XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) assay using the Cell Proliferation Kit II (Roche Molecular Biochemicals, Mannheim, Germany) according to the instructions of the manufacturer. Absorption was measured 4 h after addition of XTT reagent at 450 nm using a Biotek SynergyTM HT microplate reader (BioTek Instruments, Inc, Vermont, USA) and IC₅₀ values were calculated by using Graph Pad Prism 5 software. Experiments were performed threefold for melanoma cells and sixfold for fibroblasts, and data are given as means \pm SD.

Immunoblotting

For immunoblot analysis cells were harvested in RIPA (RadioImmunoPrecipitationAssay) buffer (50 mM Tris-HCL (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% SDS), supplemented with a protease inhibitor mix (Proteoblock, Fermentas). Forty microgramm of total protein extract were denatured in electrophoresis sample buffer for 5 min

at 95°C, and subjected to SDS-polyacrylamide gel electrophoresis (PAGE). Gels were blotted onto nitrocellulose membranes (Protran BA83 Nitrocellulose Transfer membrane, Whatman). Immunodetection was performed using the following primary antibodies anti-p-cJun (Ser63/73) mouse monoclonal Ab (sc-16312, Santa Cruz Biotechnology, Dallas, USA), anti p53 mouse monoclonal Ab (BD Pharmingen™, Becton Dickinson, Franklin Lakes, NJ, USA), and anti-GAPDH mouse monoclonal Ab (MAB374, Millipore Corporation, Billerica, MA, USA). For loading control, immunoblots were performed with an anti-GAPDH mouse monoclonal Ab (MAB374, Millipore, Billerica, USA). The secondary antibody IRDye 800CW goat-anti-mouseIgG (926-32210, LI-COR Biosciences, Bad Homburg, Germany) was used for immunodetection. Detection and quantification of protein bands was performed with a LI-COR Odyssey scanner (LI-COR Biosciences) using Odyssey 3.0 analytical software (LI-COR Biosciences).

Kinase ATP binding assay

To test the inhibitory activity of indirubins on c-Jun N-terminal kinase activity (JNK2/MAPK9), a LanthaScreen® Eu Kinase Binding Assay was performed according to the instructions of the manufacturer (Invitrogen, Madison, WI, USA). In brief, the test compound was diluted in a range from 0-10 µM for sorafenib and 0-100 µM for the different indirubins. Five microliter of each dilution was added in triplicate in a 348-well plate. Five µl of kinase/antibody solution consisting of 15 nM kinase (MAPK9; PV3620), 6 nM biotin anti-His tag antibody (PV6089) and 6 nM Eu-streptavidin, (PV5899), and 5 µl tracer 199 solution (30 nM; PV5830) were added. Plates were incubated for 1 hour at room temperature in the dark. Finally, plates were read with the SpectraMax M5 microplate reader (Molecular Devices, Life Technologies, Biberach an der Riss, Germany) with excitation at 340 nm and emission was measured at 665 nm and 615 nm. Emission ratio was calculated by dividing the acceptor/tracer emission (665 nM) by the antibody/donor emission (615 nM). Compound concentrations were plotted versus emission ratio and sigmoidal dose-response curves were fitted to generate the IC₅₀ values with the Origin 8G software.

Quantification of cell viability, cell proliferation and real-time cell analysis

Cell viability at the single cell level was monitored by the life-cell labeling dye calcein-AM. Briefly, 10⁵ cells were incubated with calcein (4 µM; eBioscience, Frankfurt, Germany) in

serum-free growth medium (60 min, 37°C). After PBS washing, cell viability was determined by flow cytometry, comparing calcein-stained (viable) and unstained (dead) cells. Cytotoxicity was determined in parallel by measuring LDH activity in culture fluids applying a cytotoxicity detection assay (Roche Diagnostics). For growth curve determination, cell confluence was continuously monitored by real-time cell analysis (xCELLigence, ACEA Biosciences, San Diego, CA). The technique is based on microelectrodes integrated in the bottom of the wells of special 96-well E-plates. The electric impedance corresponds to the cell density. 1,250 cells were seeded per microtiter well, and treatment started after 24 h. The impedance was determined up to 100 h after seeding. Cell proliferation was furthermore quantified according to the cleavage of the water-soluble tetrazolium salt WST by mitochondrial dehydrogenases in viable cells (WST-1 assay, Roche Diagnostics). Cells were seeded in a density of 5,000 per 100 µl in 96-well plates, and treatment started after 24 h. At the time of analysis, WST-1 reagent was added and absorbance at 450 nm was determined in an ELISA reader. Data were reported in percent of non-treated controls.

Acknowledgement

Financial support by the State of Mecklenburg-Western Pommerania, the Deutsche Forschungsgemeinschaft and the Deutsche Krebshilfe (Melanomverbund, grant numbers 108008 TP5 and TP7) are gratefully acknowledged. Analysis of data from the kinase ATP binding assays was supported by F. Gaunitz, Clinic for Neurosurgery, University of Leipzig.

References

1. (a) Xiao, Z.; Hao, Y.; Liu, B.; Qian, L. *Leukemia Lymphoma* **2002**, *43*, 1763–1768.
2. (a) Hoessel, R.; Leclerc, S.; Endicott, J. A.; Nobel, M. E. M.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. *Nat. Cell Biol.* **1999**, *1*, 60–67. (b) Moon, M. J.; Lee, S. K.; Lee, J.-W.; Song, W. K.; Kim, S. W.; Kim, J. I.; Cho, C.; Choi, S. J.; Kim, Y.-C. *Bioorg. Med. Chem.* **2006**, *14*, 237–246.
3. (a) Sausville, E. A.; Zaharevitz, D.; Gussio, R.; Meijer L.; Louarn-Leost, M.; Kunick, C.; Schultz, R.; Lahusen, T.; Headlee, D.; Stinson, S.; Arbutck, S. G.; Senderowicz, A.

- Pharmacol. Therapeut.* **1999**, *82*, 285–292. (b) Fischer, P. M.; Lane, D. P. *Curr. Med. Chem.* **2000**, *7*, 1213–1245.
4. Beauchard, A.; Ferandin, Y.; Frere, S.; Lozach, O.; Blairvacq, M.; Meijer, L.; Thiery, V.; Besson, T. *Bioorg. Med. Chem.* **2006**, *14*, 6434–6443.
5. Review: Karapetyan, G.; Chakrabarty, K.; Hein, M.; Langer, P. *ChemMedChem* **2011**, *6*, 25–37.
6. (a) Sassatelli, M.; Saab, E.; Anizon, F.; Prudhomme, M.; Moreau, P. *Tetrahedron Lett.* **2004**, *45*, 4827–4830. (b) Sassatelli, M.; Bouchikhi, F.; Messaoudi, S.; Anizon, F.; Debiton, E.; Barthomeuf, C.; Prudhomme, M.; Moreau, P. *Eur. J. Med. Chem.* **2006**, *41*, 88–100. (c) Sassatelli, M.; Bouchikhi, F.; Aboab, B.; Anizon, F.; Doriano, F.; Prudhomme, M.; Moreau, P. *Anti-Cancer Drugs* **2007**, *18*, 1069–1074. (d) Wang, L.; Liu, X.; Chen, R. U.S. Patent 6,566,341, **2003**; *Chem. Abstr.* *138*: 379213. (e) Wang, L.; Liu, X.; Chen, R. WO Patent 03051900, **2003**; *Chem. Abstr.* *139*: 47135.
7. (a) Libnow, S.; Hein, M.; Michalik, D.; Langer, P. *Tetrahedron Lett.* **2006**, *47*, 6907–6909. (b) Libnow, S.; Methling, K.; Hein, M.; Michalik, D.; Harms, M.; Wende, K.; Flemming, A.; Koeckerling, M.; Reinke, H.; Bednarski, P. J.; Lalk, M.; Langer, P. *Bioorg. Med. Chem.* **2008**, *16*, 5570–5583.
8. (a) Erben, F.; Kleeblatt, D.; Sonneck, M.; Hein, M.; Feist, H.; Fahrenwaldt, T.; Fischer, C.; Matin, A.; Iqbal, J.; Ploetz, M.; Eberle, J.; Langer, P. *Org. Biomol. Chem.* **2013**, *11*, 3963–3978. (b) Kleeblatt, D.; Siyo, B.; Hein, M.; Iaroshenko, V. O.; Iqbal, J.; Villinger, A.; Langer, P. *Org. Biomol. Chem.* **2013**, *11*, 886–895. (c) Kunz, M.; Driller, K. M.; Hein, M.; Libnow, S.; Hohensee, I.; Ramer, R.; Hinz, B.; Berger, A.; Eberle, J.; Langer, P. *ChemMedChem* **2010**, *5*, 534–539. (d) Libnow, S.; Hein, M.; Langer, P. *Synlett* **2009**, 221–224. (e) Libnow, S.; Hein, M.; Langer, P. *Tetrahedron Letters* **2008**, *49*, 289–291. (f) Kleeblatt, D.; Cordes, C. A.; Lebrezn, P.; Hein, M.; Feist, H.; Matin, A.; Raza, R.; Iqbal, J.; Munshi, O.; Rahman, Q.; Villinger, A.; Langer, P. *RSC Advances* **2014**, *4*, 22828. (g) Erben, F.; Michalik, D.; Feist, H.; Kleeblatt, D.; Hein, M.; Matin, A.; Iqbal, J.; Langer, P. *RSC Advances* **2014**, *4*, 10879.
9. (a) Woodard, C. L.; Li, Z.; Kathcart, A. K.; Terrell, J.; Gerena, L.; Lopez-Sanchez, M.; Kyle, D. E.; Bhattacharjee, A. K.; Nichols, D. A.; Ellis, W.; Prigge, S. T.; Geyer, J. A.; Waters, N. C. *J. Med. Chem.*, **2003**, *46*, 3877–3882. (b) Belenkaya, R. S.; Boreko, E. I.

- Zemtsova, M. N.; Kalinina, M. I.; Timofeeva, M. M., *Pharm. Chem. J.* **1981**, *15*, 171–176. (c) Strigacova, J.; Hudecova, D.; Mikulasova, M.; Varecka, L.; Lasikova, A.; Vegh, D. *Folia Microbiol.* **2001**, *46*, 187–192. (d) Lockman, J. W.; Reeder, M. D.; Robinson, R.; Ormonde, P. A.; Cimbora, D. M.; Williams, B. L.; Willardsen, J. A. *ACS Chem. Biol.* **2009**, *4*, 199–208. (e) Koz'minykh, E. N.; Berezina, E. S.; Kolla, V. E.; Shelenkova, S. A.; Voronina, E. V.; Koz'minykh, V. O. *Khim. Farm. Zh.* **1997**, *31*, 31–36.
10. (a) Stollé, R. *Chem. Ber.* **1913**, *46*, 3915–3916. (b) da Silva, J. F. M.; Garden, S. J.; Pinto, A. C. *J. Braz. Chem. Soc.* **2001**, *12*, 273–324. (c) Preobrazhenskaya, M. N.; Yartseva, I. V.; Ektova, L. V., *Dokl. Chem.* **1974**, *215*, 219–222. (d) Chavis, C.; De Gourcy, C.; Dumont, F.; Imbach, J.-L. *Carbohydr. Res.* **1983**, *113*, 1–20. (e) Douglas, J. G.; Honeyman, J. *J. Chem. Soc.* **1955**, 3674–3680. (f) Preobrazhenskaya, M. N.; Yartseva, I. V.; Ektova, L. V. *Nucleic Acid Chem.* **1978**, *2*, 725–727. (g) Yartseva, I. V.; Ektova, L. V.; Preobrazhenskaya, M. N. *Bioorg. Khim.* **1975**, *1*, 189–194.
11. CCDC-1019590 (**9c**) contains all crystallographic details of this publication which are available free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html or can be ordered from the following address: Cambridge Crystallographic Data Centre, 12 Union Road, GB-Cambridge CB21EZ; Fax: (+44)1223-336-033; or deposit@ccdc.cam.ac.uk.
12. Zemplén, G.; Gerecs, A.; Hadácsy, I. *Chem. Ber.* **1936**, *69B*, 1827–1829.
13. Brüggén, J.; Sorg, C. *Cancer Immunol. Immunother.* **1983**, *15*, 200–205.
14. Berger, A.; Quast, S. A.; Plötz, M.; Hein, M.; Kunz, M.; Langer, P.; Eberle, J. *Biochem. Pharmacol.* **2011**, *81*, 71–81.
15. Quast, S. A.; Berger, A.; Plötz, M.; Eberle, J. *Eur. J. Cell Biol.* **2014**, *93*, 42–8.

